The possibilities for gene therapies are being realized as candidates come to market with hundreds more in development. Adeno-associated virus (AAV) is a common vector, yet current production, purification, and analytics are far from optimal.
Watch Now
genengnews.com
The voyage of a cell or gene therapy from initial hypothesis to commercial delivery is complex and challenging. It requires a broad spectrum of scientific expertise, innovative technologies, and optimized processes to ensure these advanced therapeutics make it to market. In this GEN webinar, our panelists—two industry leaders—will discuss what it takes to develop a cell or gene therapy from concept to commercialization, alongside a conversation about innovations that are likely to shape the future of advanced therapy discovery and biomanufacturing.
Watch Now
genengnews
Toxicity failures caused by off-target or unintended on-target liabilities are a leading cause of attrition in clinical and preclinical programs. Given the effort, cost, and technical limitations of traditional biopharmaceutical de-risking strategies, there is a need for a robust and scalable approach that can be rapidly applied to the discovery phases of therapeutic programs. Join us for this exciting new GEN Webinar, where our panel of experts will discuss new approaches to de-risking lead selection of antibodies and other biotherapeutics.
Watch Now
workcast
The advent of single cell approaches for studying chromatin accessibility, including single-cell ATAC-seq and single-cell RNA-seq, has enabled characterization of epigenomes at single cell resolution. These studies contribute to a systems-level understanding of epigenomic variation at the single-cell level, allowing detection and assessment of an important driver of cell-to-cell heterogeneity.
Watch Now